Table 1.
Summary of the phage-antibody treatment procedures conducted in the patients who participated in this study
| Patient ID | Tumor histology | Dose of phage scFv library, TUs/kg (Body weight, kg) | Location(s) of tumor resection | Size of excised tumor | Side effects during infusion | Side effects post-infusion days 2–60 |
|---|---|---|---|---|---|---|
| 180-12 | Granulocytic lymphoma | 1 × 1011 (91.08) | Left chest wall, high axillary area-left pectoralis muscle | 2 × 2 × 2 cm | None | Please see footnotea |
| 180-13 | Colorectal metastasis to liver | 1 × 1011 (95.79) | Pedunculated hanging tumor-right posterior lateral liver, segment VI | 6 × 5 × 4 cm | None | None |
| 180-14 | Chondrosarcoma metastasis to pelvis | 1 × 1011 (85.05) | Pelvic mass | 21 × 11.5 × 10.5 cm | None | None |
| 180-15 | Melanoma metastasis to lymph node | 1 × 1011 (83.00) | Left axillary mass | 16 × 12 × 12 cm | None | Please see footnoteb |
| 180-16 | Melanoma metastasis to liver | 1 × 1011 (53.10) | Liver resection partial segmentectomy of segment VI | 1.6 cm diameter × 1.9 cm length | None | None |
| 180-17 | Metastatic melanoma | 1 × 1011 (91.7) | Subcutaneous mass excised from right posterior thigh | 1.5 cm diameter × 1.5 cm length | None | None |
aOne-month follow-up: low values for blood HGB, HCT, ANC, platelets, albumin, and total protein; high levels of alkaline phosphatase. Two-month follow-up: ANC returned to normal levels, other side effects remained, attributed to progressive metastatic disease, and/or response to chemotherapy
bNo complications were reported at 1-week follow-up visit. The patient came to ER about 1.5 months after the infusion with nausea, vomiting, and neck pain. An obstruction was treated with a stent in the superior vena cava. At 2-month follow-up, it was noted that continued side effects were related to the growth of the malignant melanoma